source
- FDA sets May 1 decision deadline for UniQure’s Huntington’s disease gene therapy after advisory committee meetingThe U.S. Food and Drug Administration announced that it has set a review date and scheduled an advisory committee meeting for UniQure’s gene therapy aimed at treating Huntington’s disease. The age…
- Tiziana's lower-dose foralumab cuts neuroinflammation in SPMS, but higher dose failsTiziana Life Sciences reported that its intranasal anti‑CD3 antibody, foralumab, lowered a neuroinflammation biomarker in patients with non‑active secondary progressive multiple sclerosis when give…